AC
RLAY icon

Allstate Corporation’s Relay Therapeutics RLAY Stock Holding History

Allstate Corporation’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,600
Closed -$264K – 732
2021
Q4 		$264K Buy
+8,600
New +$272K 0.01% 729

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Allstate Corporation's RLAY Position: Q1 2022 in Review

Allstate Corporation sold out of Relay Therapeutics (RLAY) in Q1 2022, closing a stake of 8,600 shares — an estimated $264K sold.

Allstate Corporation first reported a position in RLAY in Q4 2021 and held it in 1 quarter. The position peaked at $264K in Q4 2021. 140 funds tracked by Wall St. Rank hold RLAY as of Q1 2022.

  • Allstate Corporation reported no remaining Relay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Allstate Corporation sold 8,600 Relay Therapeutics shares in Q1 2022, an estimated $264K.
  • Allstate Corporation first reported a position in Relay Therapeutics in Q4 2021 and held it in 1 quarter.
  • Allstate Corporation's Relay Therapeutics position peaked at $264K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2022.

Based on Allstate Corporation's 13F filing for Q1 2022, filed 16 May 2022.